Neurotherapeutics is the official journal of the American Society for Experimental NeuroTherapeutics (ASENT). Originally published by the society itself in 2004 as NeuroRx, the journal was transitioned to Elsevier in 2007, at which time it was renamed Neurotherapeutics. Throughout the 6-year history of the journal, critical reviews have been exclusively published as thematic issues on topics related to the treatment of nervous system disorders.
Each quarterly issue is developed by one or more distinguished guest editors who are an expert in the topic area. The guest editors solicit the review articles and arrange for peer review. The journal is indexed in MEDLINE/PubMed, Science Citation Index Expanded, Current ContentsClinical Medicine, and Current Contents-Life Sciences. The journal has been indexed by Thomson Reuters and in June 2010 received its first Impact Factor rating-5.381-an impressive measure of the journal's success as tracked over the last 3 years. The average citation per article is 7.13 and the number of article downloads per month has steadily increased to more than 12,000 per month.
We are pleased to announce that in January 2011 the journal will begin its publication of high quality, original research articles in translational neuroscience. We invite you to submit your best research for consideration beginning September 2010. Instructions for authors will be posted on the journal's website.
When the journal was originally founded by ASENT, the society's publication oversight board intended for the journal to eventually publish high impact, original research of broad interest to the neurotherapeutics community. Neurotherapeutics is now sufficiently established to realize this vision. The journal will continue to publish invited reviews. We also look forward to the new role for the journal to be a premier vehicle for the communication of basic science and clinical research in neuroscience-related therapeutics. Accepted, peer-reviewed, original research articles will be published electronically as soon as they are typeset, and they will also be included in the next quarterly printed issue. All content will be contributed to PubMed Central, the electronic publishing platform of the National Library of Medicine. The commitment to PubMed Central for the journal will ensure the widest possible access and will provide for an archival repository of the content. In addition, because every article we publish will be included in PubMed Central, authors will be relieved of the task of making submissions independently if required by their granting agencies.
We are confident that the field of neurotherapeutics will benefit from having a journal that focuses on the publication of groundbreaking translational neuroscience research, and we look forward to submissions from our readers and scientists worldwide.
